BERLIN, Germany and NICE, France, June 16, 2010
BIOTRONIK SE & Co KG, the pioneer in wireless remote monitoring technology for patients with cardiac devices, today announced the tenth anniversary of BIOTRONIK Home Monitoring® —the world’s first wireless, mobile patient monitoring technology—to be celebrated during Cardiostim in Nice, France.
Today, hundreds of thousands of BIOTRONIK Home Monitoring systems have been implanted, giving patients with heart pacing and fibrillation issues a new level of independence and confidence. At the earliest sign of a problem, their physicians receive immediate notification no matter if they are at home or thousands of miles away. With this potentially life-saving information, doctors can contact their patients in real time and send them to the hospital if immediate treatment is necessary. In clinical trials, the BIOTRONIK Home Monitoring system has been proven to reduce the time between cardiac event onset to patient evaluation by nearly a month compared to devices without remote home monitoring.1
BIOTRONIK has spent the last decade perfecting the concept of online patient monitoring and follow-ups with several technological innovation milestones, from the introduction of the world’s first remote monitoring system for implanted cardiac rhythm devices in 2000, to the first internet-based system, to the most advanced remote patient monitoring technology with an intelligent traffic light concept.
Ten years ago, BIOTRONIK conducted the first technical application and feasibility studies for Home Monitoring. BIOTRONIK pacemakers communicated daily and—upon event detection—sent an alert via an integrated antenna to the world’s first wireless, mobile patient device. The patient data was then immediately sent to the attending physician on a consolidated CardioReport®. Based on this, BIOTRONIK Home Monitoring earned FDA and CE approval for remote monitoring of patients with implantable BIOTRONIK pacemakers and cardiac defibrillators. Then in 2003, BIOTRONIK globally launched a new wireless, cellular patient device, CardioMessenger®, and an internet-based Home Monitoring technology allowing physician access from anywhere and at any time.
The introduction of bidirectional telemetry in 2006 significantly increased the quantity of transmitted data for remote follow-up, including the industry’s first high-definition IEGM transmissions (IEGM-Online HD®), allowing for more complete remote monitoring of patient and device status. In 2008, the landmark TRUST1 trial proved that BIOTRONIK Home Monitoring can safely replace in-hospital follow-ups and provides early detection and notification of both symptomatic and asymptomatic arrhythmic events allowing for earlier physician intervention. A regulatory confirmation followed in 2009 resulting in an exclusive expansion of FDA and CE approvals for BIOTRONIK Home Monitoring.
“The future innovations of BIOTRONIK Home Monitoring will be diverse and include many promising diagnostic, monitoring and sensor technologies to optimize patient care with a focus on heart failure patient management,” said Dr. Hans-Jürgen Wildau, BIOTRONIK Vice President of Health Services. “BIOTRONIK will continue its long tradition of pioneering leadership, offering the most advanced patient management system and is just as determined to set the pace well into the next decade with new diagnostic options and monitoring technologies.”
About BIOTRONIK SE & Co. KG
As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,100 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
1Varma N. et al. Evaluation of efficacy and safety of remote monitoring for ICD follow-up: the TRUST trial (abstract 4078). Circulation. 2008; 118;231
|Link to EON Business
For more information about Home Monitoring, please click here